Adalat LA 60 tablets

Country: United Kingdom

Language: English

Source: MHRA (Medicines & Healthcare Products Regulatory Agency)

Active ingredient:

Nifedipine

Available from:

Sigma Pharmaceuticals Plc

ATC code:

C08CA05

INN (International Name):

Nifedipine

Dosage:

60mg

Pharmaceutical form:

Modified-release tablet

Administration route:

Oral

Class:

No Controlled Drug Status

Prescription type:

Caution - AMP level prescribing advised

Product summary:

BNF: 02060200

Patient Information leaflet

_325 LEAFLET Adalat LA 20180731 _
PACKAGE LEAFLET: INFORMATION FOR USER
ADALAT
® LA 60 TABLETS
(nifedipine)
Your medicine is known as Adalat LA 60 Tablets but will be referred
to as Adalat LA throughout the following leaflet.
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU.
Keep this leaflet. You may need to read it again.
If you have any further questions, ask your doctor or pharmacist.
This medicine has been prescribed for you only.
Do not pass it on to others. It may harm them, even if their signs of
illness are the same as yours.
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side effects not listed in this leaflet. See
section 4.
WHAT IS IN THIS LEAFLET
1.
WHAT ADALAT LA IS AND WHAT IT IS USED FOR
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE ADALAT LA
3.
HOW TO TAKE ADALAT LA
4.
POSSIBLE SIDE EFFECTS
5.
HOW TO STORE ADALAT LA
6.
CONTENTS OF THE PACK AND OTHER INFORMATION
1. WHAT ADALAT LA IS AND WHAT IT IS USED FOR
Adalat LA contains nifedipine, which belongs to a group of
medicines called _calcium antagonists. _
ADALAT LA IS USED TO TREAT HIGH BLOOD PRESSURE OR ANGINA _(chest _
_pain). _
For high blood pressure: Adalat LA works by relaxing and
expanding the blood vessels. This makes the blood flow more
easily and lowers blood pressure. Lower blood pressure reduces
the strain on your heart.
For angina: Adalat LA works by relaxing and expanding the arteries
supplying the heart. This allows more blood and oxygen to reach
the heart and decreases the strain on it. Your angina attacks will be
less severe and less frequent if there is less strain on the heart.
2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE ADALAT LA
DO NOT TAKE ADALAT LA:

IF YOU HAVE HAD A HEART ATTACK within the last month.

IF YOU GET A SUDDEN ANGINA ATTACK. Adalat LA will not help
relieve symptoms of angina quickly.

IF YOU HAVE UNSTABLE ANGINA.

IF YOU ARE ALLERGIC to nifedipine, any other similar medicines
(known as _dihy

Summary of Product characteristics

SUMMARY OF PRODUCT CHARACTERISTICS
1
NAME OF THE MEDICINAL PRODUCT
Adalat LA 60 mg prolonged-release tablets
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each prolonged-release tablet contains 60 mg nifedipine.
Each tablet contains a 10% overage of nifedipine to deliver the label
claim.
For the full list of excipients, see section 6.1.
3
PHARMACEUTICAL FORM
Prolonged-release film-coated tablet.
Pink, round, convex tablet with a laser hole on one side and marked
with Adalat 60.
4.
CLINICAL PARTICULARS
4.1.
THERAPEUTIC INDICATIONS
For the treatment of all grades of hypertension.
For the prophylaxis of chronic stable angina pectoris either as
monotherapy or
in combination with a beta-blocker.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
_Posology _
In mild to moderate hypertension, the recommended initial dose is one
20 mg tablet
once-daily. In severe hypertension, the recommended initial dose is
one 30 mg tablet
once-daily. If necessary, the dosage can be increased according to
individual
requirements up to a maximum of 90 mg once-daily.
For the prophylaxis of angina pectoris, the recommended initial dose
is one 30 mg
tablet once-daily. The dosage can be increased according to individual
requirements
up to a maximum of 90 mg once-daily.
Patients in whom hypertension or anginal symptoms are controlled on
Adalat
capsules or Adalat retard may be safely switched to Adalat LA.
Prophylactic anti-
anginal efficacy is maintained when patients are switched from other
calcium
antagonists such as diltiazem or verapamil to Adalat LA. Patients
switched from
other calcium antagonists should initiate therapy at the recommended
initial dose of
30 mg Adalat LA once-daily. Subsequent titration to a higher dose may
be initiated
as warranted clinically.
Co-administration with CYP 3A4 inhibitors or CYP 3A4 inducers may
result in the
recommendation to adapt the nifedipine dose or not to use nifedipine
at all (see
section 4.5).
_Duration of treatment _
Treatment may be continued indefinitely.
_Additional information on special populations _
_